Sanofi

Investment and partnership decisions ultimately roll up to CEO Paul Hudson, who has driven the firm's strategic pivot since 2019. Day-to-day execution is managed through the business development and R&D leadership teams. Sanofi does not operate a standalone, publicly branded venture-capital arm; instead, equity stakes and collaboration agreements are negotiated within the therapeutic-area teams, giving scientific leads significant influence over which platform companies receive capital.

Sanofi uses its corporate venture activity primarily as a pipeline-extending and manufacturing-sourcing tool, not as a return-on-investment vehicle. It typically takes minority stakes with pre-negotiated acquisition rights or supply agreements attached, giving it biological and manufacturing visibility before committing to full buyouts. By contrast, a traditional biotech VC fund prioritizes financial returns across a diversified portfolio and rarely attaches commercial production rights to its equity checks.

Sanofi targets preclinical and clinical-stage biotech companies working in its priority therapeutic areas: immunology, oncology, rare disease, and vaccines. The firm also invests in platform and enabling-technology companies that support drug discovery, manufacturing, and artificial intelligence applied to clinical development. It generally enters after a platform is scientifically de-risked but before Phase III trials, when structured collaboration economics are most beneficial to both parties.

Sanofi's recent restructuring explicitly lowered priority on mature primary-care products and consumer health, a unit it moved to separate. The firm has not publicly identified therapeutic areas it will absolutely never invest in, but the stated pipeline focus on specialty care, vaccines, and rare disease signals reduced appetite for commoditized small-molecule categories or over-the-counter brands where its manufacturing advantages do not apply.

Sanofi's "EVolutive Facilities" in France and Singapore are designed to switch production between multiple biologic products quickly. This flexibility gives the firm an edge in structuring venture deals: it can offer a potential partner not just capital but guaranteed production capacity upon regulatory success. Many biotech start-ups lack the balance sheet to build their own manufacturing, making Sanofi's combined capital-and-capacity offer distinctive in venture-stage negotiations.